Rationing Medications: How Ethical Decisions Are Made During Drug Shortages

8March

When a life-saving drug runs out, who gets it? This isn’t a hypothetical question anymore. In 2023, over 319 medications were in short supply across the U.S., including critical cancer drugs like carboplatin and cisplatin. Hospitals faced impossible choices: give the last dose to a patient with a 70% chance of survival, or hold it for someone with a 30% chance? These aren’t decisions made in boardrooms-they’re made at the bedside, under pressure, with no clear rules. And that’s the problem.

Why rationing happens-and why it’s unavoidable

Drug shortages aren’t new, but they’ve gotten worse. In 2005, there were 61 shortages. By 2023, that number jumped to 319. The biggest culprits? Generic injectable drugs, especially those used in cancer treatment, ICU care, and emergency medicine. Why? Because a handful of manufacturers control most of the supply. Just three companies make 80% of generic sterile injectables. If one plant shuts down for quality issues-or if raw materials get delayed-the whole system stumbles.

When demand outstrips supply, doctors can’t just prescribe what’s on the shelf. They’re forced to ration. And without a system, that means luck, bias, or who speaks loudest wins. A 2022 study found that over half of all rationing decisions were made by individual clinicians without any formal guidance. That’s not healthcare. That’s triage without a plan.

The ethical principles behind fair allocation

Ethical rationing isn’t about picking who lives or dies. It’s about making sure every decision follows clear, fair, and transparent rules. The most widely accepted framework comes from bioethicists Daniel and Sabin, called “accountability for reasonableness.” It has four rules:

Publicity: Everyone must know how decisions are made.
Relevance: Criteria must be based on medical evidence, not personal opinion.
Appeals: Patients and families must be able to challenge decisions.
Enforcement: Someone must make sure the rules are followed.

These aren’t just nice ideas. They’re the bare minimum. A 2023 ASCO guideline added three more: decisions should be made at the institutional level (not by one doctor), involve a team (not one person), and include clear communication with patients.

What criteria actually get used?

So, how do you decide who gets the last dose? There’s no single answer-but experts agree on five key factors:

Urgency of need: Is the patient in immediate danger without the drug?
Chance of benefit: How likely is the treatment to work? For example, carboplatin works best in early-stage ovarian cancer with no other options.
Duration of benefit: Will this drug give months of life-or just weeks?
Years of life saved: Should we prioritize a 30-year-old over a 75-year-old if both have equal survival odds?
Instrumental value: Should frontline healthcare workers get priority if they’re essential to keeping the system running?

The Minnesota Department of Health took this further. In their 2023 carboplatin guidance, they defined exact priority tiers:

Tier 1: Curative intent, no alternative treatment available.
Tier 2: Palliative intent, but expected survival benefit of more than 6 months.
Tier 3: Other uses, where alternatives exist.

This isn’t guesswork. It’s a checklist. And it’s the difference between chaos and fairness.

A hospital ethics team reviews a tiered allocation chart with glowing patient silhouettes.

Why most hospitals still get it wrong

You’d think hospitals would have this figured out by now. But they don’t. A 2018 survey of 719 hospitals found only 36% had a standing committee to handle shortages. And of those? Just 13% included doctors. Only 3% had an ethicist on the team.

That’s a disaster waiting to happen. When decisions are made by one oncologist in a rush, bias creeps in. Studies show that patients from marginalized groups-Black, Hispanic, low-income-are less likely to be informed about rationing, less likely to be prioritized, and more likely to be left out entirely.

And then there’s the human cost. Clinicians report extreme moral distress. One oncologist told a forum: “I’ve had to choose between two stage IV ovarian cancer patients for limited carboplatin doses three times this month-with no institutional guidance.” That’s not just heartbreaking. It’s unsustainable. Hospitals with formal committees saw 41% lower burnout rates. The system isn’t just broken for patients-it’s breaking the people trying to help them.

What actually works-and what doesn’t

Here’s the hard truth: bedside rationing fails. It’s fast, but it’s unfair. A 2022 JAMA study found that hospitals using committee-based systems had 32% fewer disparities in who got treatment.

But committees aren’t perfect. They take time. The average time from shortage declaration to first meeting? 72 hours. In an emergency, that’s too long. That’s why the best systems use a three-step approach:

Conservation: Use the lowest effective dose. Stretch what’s available.
Substitution: Switch to another drug with similar effectiveness.
Rationing: Only if the first two fail, use formal allocation criteria.

The hospitals that do this right also track everything. They log rationing decisions in electronic records, note why a patient was prioritized, and document whether they told the family. Only 22% of hospitals do this. The rest are flying blind.

An oncologist sits alone at night, surrounded by floating ethical criteria above their desk.

What’s changing-and what’s coming

There’s hope. In 2023, ASCO launched a free online tool to help oncology teams make allocation decisions. The FDA announced plans for an AI-powered early warning system to predict shortages before they hit. And in January 2024, pilot programs began in 15 states to certify hospital ethics committees-standardizing training, membership, and protocols.

The National Academy of Medicine is also working on national standards. Draft criteria are expected by mid-2024. This could finally create consistency: same rules in rural clinics and major hospitals.

But progress is slow. Manufacturers still aren’t required to report shortages early. Only 68% meet the 6-month notification rule. And until supply chains are more resilient, we’ll keep facing these crises.

What patients and families should know

If you or someone you love is affected by a drug shortage, here’s what to ask:

“Is this drug in short supply?”
“What are the alternatives?”
“How are decisions being made about who gets it?”
“Can I see the hospital’s rationing policy?”
“Can I appeal if I’m not chosen?”

You have a right to transparency. If your hospital can’t answer these questions, they’re not following basic ethical standards.

Medication rationing isn’t about scarcity alone. It’s about whether we’re willing to build systems that protect the most vulnerable-not just the loudest. The tools exist. The ethics are clear. What’s missing is the will to use them.

What drugs are most commonly rationed during shortages?

The most frequently rationed medications are sterile injectables, especially in oncology and critical care. These include carboplatin, cisplatin, doxorubicin, epinephrine, sodium bicarbonate, and propofol. In 2023, oncology drugs made up nearly half of all FDA-reported shortages. These drugs are hard to manufacture, have low profit margins, and rely on a few global suppliers-making them vulnerable to disruptions.

Can hospitals legally ration medications?

Yes, but only under strict ethical and procedural guidelines. There’s no federal law that says hospitals must ration, but there’s also no law that forbids it during emergencies. What matters is how they do it. Courts have upheld rationing policies that follow transparent, evidence-based, and non-discriminatory frameworks. Arbitrary decisions-like favoring wealthy patients or those with better insurance-can lead to legal liability. The key is following established ethical frameworks like those from ASCO or ASHP.

Are patients told when they’re being rationed?

Too often, no. A 2022 JAMA survey found only 36% of patients affected by rationing were informed about it. This is a major ethical failure. Transparency isn’t optional-it’s required by bioethics standards. Patients deserve to know why a treatment was delayed, changed, or denied. The ASCO 2023 guidelines now explicitly require that all patients be informed, with clear explanations and support resources.

Do ethics committees really make a difference?

Yes. Hospitals with formal, multidisciplinary ethics committees have 32% fewer allocation disparities and 41% lower clinician burnout. These committees include pharmacists, nurses, doctors, social workers, ethicists, and patient advocates. They review cases, apply consistent criteria, document decisions, and ensure fairness. Without them, rationing becomes a series of individual, emotional decisions-which leads to inconsistency and moral injury.

What can patients do if they’re denied a rationed drug?

Patients have the right to ask for an appeal process. Ethical rationing frameworks require that patients be told how to challenge a decision. If your hospital doesn’t have one, request a meeting with the ethics committee or patient advocate. You can also ask for alternatives, such as drug substitutions, clinical trials, or financial assistance programs. Organizations like the Patient Advocate Foundation and ASHP offer resources to help navigate these situations.